Frazier Life Sciences Management L.P. Has $8.94 Million Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR

Key Points

• Frazier Life Sciences Management L.P. increased its stake in Immunocore Holdings PLC by 176.9% in Q1, holding 301,170 shares worth approximately $8.94 million.
• Immunocore recently reported a revenue of $130.65 million in its latest earnings, exceeding analysts' expectations, with a year-over-year increase of 30%.
• Analyst ratings for Immunocore show an average target price of $56.89, with seven analysts recommending a "buy" rating and three a "hold."

Frazier Life Sciences Management L.P. increased its position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) by 176.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 301,170 shares of the company's stock after buying an additional 192,408 shares during the quarter. Frazier Life Sciences Management L.P. owned about 0.60% of Immunocore worth $8,936,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Immunocore by 5.2% in the first quarter. T. Rowe Price Investment Management Inc. now owns 7,051,818 shares of the company's stock valued at $209,228,000 after buying an additional 351,610 shares during the period. Primecap Management Co. CA lifted its holdings in shares of Immunocore by 0.4% in the first quarter. Primecap Management Co. CA now owns 2,678,650 shares of the company's stock valued at $79,476,000 after buying an additional 10,100 shares during the period. Baker BROS. Advisors LP lifted its holdings in shares of Immunocore by 53.3% in the first quarter. Baker BROS. Advisors LP now owns 2,322,656 shares of the company's stock valued at $68,913,000 after buying an additional 807,338 shares during the period. Tang Capital Management LLC lifted its holdings in shares of Immunocore by 40.7% in the fourth quarter. Tang Capital Management LLC now owns 1,555,600 shares of the company's stock valued at $45,890,000 after buying an additional 450,000 shares during the period. Finally, Fiera Capital Corp lifted its holdings in shares of Immunocore by 3.2% in the first quarter. Fiera Capital Corp now owns 805,150 shares of the company's stock valued at $23,889,000 after buying an additional 25,186 shares during the period. Institutional investors and hedge funds own 84.50% of the company's stock.

Immunocore Stock Up 5.5%

Shares of IMCR traded up $1.94 during trading hours on Friday, reaching $37.20. The company's stock had a trading volume of 635,305 shares, compared to its average volume of 297,189. The company has a 50 day moving average of $33.62 and a two-hundred day moving average of $31.57. The company has a quick ratio of 5.86, a current ratio of 5.89 and a debt-to-equity ratio of 1.01. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of -93.00 and a beta of 0.77. Immunocore Holdings PLC Sponsored ADR has a 1-year low of $23.15 and a 1-year high of $39.33.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.01. Immunocore had a negative net margin of 5.70% and a negative return on equity of 5.40%. The firm had revenue of $130.65 million for the quarter, compared to the consensus estimate of $122.96 million. During the same period in the previous year, the firm posted ($0.23) earnings per share. The firm's revenue was up 30.0% on a year-over-year basis. As a group, research analysts predict that Immunocore Holdings PLC Sponsored ADR will post -0.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on IMCR. HC Wainwright reaffirmed a "buy" rating and set a $100.00 target price on shares of Immunocore in a research report on Monday, June 2nd. Zacks Research downgraded Immunocore from a "strong-buy" rating to a "hold" rating in a report on Thursday. Jefferies Financial Group assumed coverage on Immunocore in a report on Monday, August 25th. They set a "buy" rating and a $48.00 target price for the company. Deutsche Bank Aktiengesellschaft assumed coverage on Immunocore in a report on Tuesday, May 27th. They set a "buy" rating and a $65.00 target price for the company. Finally, Wall Street Zen downgraded Immunocore from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Seven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $56.89.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.